Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 3
2016 1
2017 2
2018 4
2019 4
2020 3
2021 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.
Magnes T, Wagner SM, Melchardt T, Weiss L, Rinnerthaler G, Huemer F, Kopp M, Gampenrieder SP, Mayrbäurl B, Füreder T, Lenger D, Andel J, Egle A, Greil R. Magnes T, et al. Wien Klin Wochenschr. 2021 Nov;133(21-22):1131-1136. doi: 10.1007/s00508-021-01939-3. Epub 2021 Sep 15. Wien Klin Wochenschr. 2021. PMID: 34528125 Free PMC article.
Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.
Schlick K, Hohla F, Hamacher F, Hackl H, Hufnagl C, Markus S, Magnes T, Gampenrieder SP, Melchardt T, Stättner S, Hauser-Kronberger C, Greil R, Rinnerthaler G. Schlick K, et al. Among authors: magnes t. Future Sci OA. 2020 Nov 30;7(2):FSO644. doi: 10.2144/fsoa-2020-0128. Future Sci OA. 2020. PMID: 33437513 Free PMC article.
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.
Rinnerthaler G, Gampenrieder SP, Hackl H, Steiner M, Monzo-Fuentes C, Melchardt T, Magnes T, Huemer F, Westphal T, Hufnagl C, Hauser-Kronberger C, Egle A, Greil R. Rinnerthaler G, et al. Among authors: magnes t. J Clin Med. 2020 Jun 1;9(6):1663. doi: 10.3390/jcm9061663. J Clin Med. 2020. PMID: 32492882 Free PMC article.
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Egle A, Melchardt T, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Voskova D, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Weiss L, Magnes T, Pleyer L, Klingler A, Mayer J, Greil R. Egle A, et al. Among authors: magnes t. Cancer Med. 2019 Apr;8(4):1401-1405. doi: 10.1002/cam4.1980. Epub 2019 Mar 19. Cancer Med. 2019. PMID: 30888118 Free PMC article. Clinical Trial.
22 results